The unique components of AAHI’s RNA Platform allow us to rapidly design and manufacture highly potent and broadly effective vaccines in response to emerging disease. RNA vaccine and therapeutic candidates developed on AAHI’s immune-enhancing platform can be made readily accessible and available to all areas of the world.
AAHI’s RNA Platform uses antigen-generating self-amplifying RNA (saRNA) molecules fixed to the exterior of our proprietary nanostructured lipid carrier (NLC) nanoparticles.
Potent Immune Response:
Breadth of protection:
Accessibility and rapid pandemic response:
Because saRNA is bound to the outside of NLC, we can stockpile NLC, which can be stored and later complexed with saRNA to elicit production of whatever vaccine antigen is needed
Our RNA Platform enables development of equitably accessible vaccines and therapeutics to address unmet global needs.
IDRI offers world-class expertise in the design, formulation, and manufacture of vaccines, adjuvants, immunotherapies, and their components.
- Research Material Supply
- Our RNA team can evaluate our NLC delivery system with your RNA of choice.
- RNA Construct Design
- Our RNA team can express your antigen of interest using proven saRNA constructs.
- Template DNA Synthesis
- Our RNA team can clone desired self-amplifying RNA DNA templates to make RNA.
- R&D-grade RNA Manufacture
- Our RNA team can transcribe and purify RNA products in vitro.
- Characterization Essays
- Our RNA team can evaluate RNA quality and integrity of RNA and/or complexed RNA.
- Stability Testing
- Our RNA team can test the stability of RNA and/or complexed RNA products.
- Immunogenicity Testing
- Our RNA team can evaluate RNA vaccine immunogenicity in preclinical mouse models.
AAHI provides consulting services for preclinical study development with the ability to get you directly into clinic and supply for your clinical trials with regulatory support.
Contact us to test AAHI adjuvant formulations with your vaccine antigen to develop a potent, durable, and broadly effective vaccine.